The latest price target for Axsome Therapeutics (NASDAQ:AXSM) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $107.00 expecting AXSM to rise to within 12 months (a possible 13.71% upside). 51 analyst firms have reported ratings in the last year.

The latest analyst rating for Axsome Therapeutics (NASDAQ:AXSM) was provided by Cantor Fitzgerald, and Axsome Therapeutics reiterated their overweight rating.

The last upgrade for Axsome Therapeutics Inc happened on August 6, 2024 when B of A Securities raised their price target to $106. B of A Securities previously had a neutral for Axsome Therapeutics Inc.

There is no last downgrade for Axsome Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Axsome Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Axsome Therapeutics was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Axsome Therapeutics (AXSM) rating was a reiterated with a price target of $107.00 to $107.00. The current price Axsome Therapeutics (AXSM) is trading at is $94.10, which is out of the analyst’s predicted range.